These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
39 related articles for article (PubMed ID: 7887241)
21. Objectives and mechanism of iron chelation therapy. Hershko C; Link G; Konijn AM; Cabantchik ZI Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658 [TBL] [Abstract][Full Text] [Related]
22. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine. Giardina PJ; Grady RW Semin Hematol; 1995 Oct; 32(4):304-12. PubMed ID: 8560288 [TBL] [Abstract][Full Text] [Related]
23. A systematic review and meta-analysis of deferiprone monotherapy and in combination with deferoxamine for reduction of iron overload in chronically transfused patients with β-thalassemia. Kuo KH; Mrkobrada M Hemoglobin; 2014; 38(6):409-21. PubMed ID: 25307964 [TBL] [Abstract][Full Text] [Related]
24. Iron overload in β-thalassemia intermedia: an emerging concern. Musallam KM; Cappellini MD; Taher AT Curr Opin Hematol; 2013 May; 20(3):187-92. PubMed ID: 23426199 [TBL] [Abstract][Full Text] [Related]
25. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia. Saliba AN; El Rassi F; Taher AT Expert Rev Hematol; 2016; 9(2):151-68. PubMed ID: 26613264 [TBL] [Abstract][Full Text] [Related]
26. [Therapeuetic management of patients with thalassemia major]. Thuret I Bull Soc Pathol Exot; 2001 May; 94(2):95-7. PubMed ID: 11475036 [TBL] [Abstract][Full Text] [Related]
27. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Delea TE; Edelsberg J; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD Transfusion; 2007 Oct; 47(10):1919-29. PubMed ID: 17880620 [TBL] [Abstract][Full Text] [Related]
28. Recent developments in iron chelation therapy. Cario H; Janka-Schaub G; Janssen G; Jarisch A; Strauss G; Kohne E Klin Padiatr; 2007; 219(3):158-65. PubMed ID: 17525910 [TBL] [Abstract][Full Text] [Related]
29. Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies. Porter JB; Shah FT Hematol Oncol Clin North Am; 2010 Dec; 24(6):1109-30. PubMed ID: 21075283 [TBL] [Abstract][Full Text] [Related]
30. Clinical management of beta-thalassemia major. Wonke B Semin Hematol; 2001 Oct; 38(4):350-9. PubMed ID: 11605170 [TBL] [Abstract][Full Text] [Related]
31. Results from a phase I clinical trial of HBED. Grady RW; Salbe AD; Hilgartner MW; Giardina PJ Adv Exp Med Biol; 1994; 356():351-9. PubMed ID: 7887241 [TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. Kontoghiorghe CN; Kontoghiorghes GJ Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541 [TBL] [Abstract][Full Text] [Related]
33. Deferasirox for managing iron overload in people with thalassaemia. Meerpohl JJ; Antes G; Rücker G; Fleeman N; Motschall E; Niemeyer CM; Bassler D Cochrane Database Syst Rev; 2012 Feb; (2):CD007476. PubMed ID: 22336831 [TBL] [Abstract][Full Text] [Related]
35. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases. Barman Balfour JA; Foster RH Drugs; 1999 Sep; 58(3):553-78. PubMed ID: 10493280 [TBL] [Abstract][Full Text] [Related]